Insider Trading

Notable insider buying and selling activity across public companies.

Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.

Articles

1,344 total articles

Intuitive Machines Finance Chief Sells $445K of LUNR to Cover RSU Taxes as Sector Sees Major Moves

Intuitive Machines Finance Chief Sells $445K of LUNR to Cover RSU Taxes as Sector Sees Major Moves

Intuitive Machines SVP and CFO Peter McGrath disposed of 25,541 shares of Class A common stock on February 11, 2026, raising about $445,332 to meet tax-withholding requirements tied to restricted stock units. The sale was not a discretionary trade. Recent volatility in LUNR shares and several industry developments - including a $1.25 trillion merge…

Palisade Bio CMO Sells Portion of Shares to Cover RSU Taxes; Holds 13,263 Shares After Transactions

Palisade Bio CMO Sells Portion of Shares to Cover RSU Taxes; Holds 13,263 Shares After Transactions

Mitchell Lawrence Jones, Chief Medical Officer of Palisade Bio, sold 1,989 shares at $1.75 on February 12, 2026, to satisfy tax-withholding tied to RSU vesting. Jones also received 8,000 shares via settlement of vested RSUs on February 11, 2026, and now directly owns 13,263 shares, including 3,400 acquired under the company ESPP. The company has re…

Royal Caribbean International CEO Disposes $26.1M in Shares as Company Posts In-Line Q4 Results and Receives Rating Upgrade

Royal Caribbean International CEO Disposes $26.1M in Shares as Company Posts In-Line Q4 Results and Receives Rating Upgrade

Michael W. Bayley, President and CEO of Royal Caribbean International, sold 79,894 shares of Royal Caribbean Cruises Ltd. common stock in a set of transactions on February 13, 2026, at prices between $322.66 and $332.19 for a total of $26,145,463. After the disposals, Bayley retains direct ownership of 58,108 shares. Separately, Royal Caribbean rep…

Ionis Research EVP Sells $1.27M in Stock as Company Posts Multiple Clinical and Regulatory Milestones

Ionis Research EVP Sells $1.27M in Stock as Company Posts Multiple Clinical and Regulatory Milestones

Eric Swayze, Executive Vice President of Research at Ionis Pharmaceuticals (IONS), sold 15,642 shares on February 13, 2026, in two transactions totaling roughly $1.27 million under a Rule 10b5-1 plan. The stock has risen sharply over the past year and is trading near its 52-week high as the company reports several clinical and regulatory achievemen…

Mineralys CMO Sells $569,809 in Stock While Exercising Options; Company Advances Lorundrostat Program

Mineralys CMO Sells $569,809 in Stock While Exercising Options; Company Advances Lorundrostat Program

Mineralys Therapeutics Chief Medical Officer David Malcom Rodman sold 14,676 shares of the companys common stock for roughly $569,809 across February 12 and 13, 2026, while exercising options to acquire 14,056 shares valued at $102,340. The trades were executed under a Rule 10b5-1 plan adopted October 6, 2025. Separately, the companys lead candidat…

BlackRock Senior Managing Director Disposes of $2.34M in Stock; Firm Sees Positive Analyst Response to Q4

BlackRock Senior Managing Director Disposes of $2.34M in Stock; Firm Sees Positive Analyst Response to Q4

Stephen Cohen, a senior managing director at BlackRock, sold 2,179 shares of the company's common stock on February 11, 2026, at $1,073.87 per share, yielding $2.34 million. The firm’s strong fourth-quarter results prompted upward price-target revisions from UBS and Keefe, Bruyette & Woods, while governance and leadership movements - including a ne…